$AXSM on POSSIBLE PLUMMETS

29 Nis 2020

AXSM clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system, it is accelerating the completion of the ADVANCE-1 Phase 2/3 trial of AXS-05 in patients with Alzheimer’s disease agitation to ensure the safety of this vulnerable patient population during the COVID-19 pandemic. i expect that this end of the month its increasing thoroughly. Are you guys ready to get through resistance? why not?